BDX — Becton, Dickinson and Company stock price, charts and financials

QT54Becton, Dickinson and Company

Becton, Dickinson and Company (NYSE: BDX) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
179.80
+0.70+0.39%
BDXQT54Becton, Dickinson and Company·NYSE
179.80+0.39%
TA
Loading chart...
Screen all →
Snapshot
IndexS&P 500P/E54.16EPS (ttm)3.32Insider Own0.27%Shs Outstand275.54MPerf Week-3.91%
Market Cap49.54BForward P/E13.53EPS next Y13.29Insider Trans-1.62%Shs Float274.94MPerf Month0.09%
Enterprise Value65.64BPEG8.23EPS next Q4.06Inst Own-Short Float3.41%Perf Quarter18.26%
Income941.00MP/S2.38EPS this Y281.64%Inst Trans-Short Ratio3.92Perf Half Y9.71%
Sales20.84BP/B2.03EPS next Y4.91%ROA1.85%Short Interest9.37MPerf YTD17.85%
Book/sh88.62P/C69.88EPS next 5Y6.58%ROE3.79%52W High193.06 -6.87%Perf Year19.38%
Cash/sh2.57P/FCF19.53EPS past 3/5Y-0.28% 16.56%ROIC3.72%52W Low127.59 40.92%Perf 3Y-17.87%
Dividend Est.4.20 (2.34%)EV/EBITDA16.84Sales past 3/5Y4.99% 6.32%Gross Margin46.12%Volatility2.30% 2.14%Perf 5Y-6.86%
Dividend TTM3.98 (2.21%)EV/Sales3.15EPS Y/Y TTM-43.34%Oper. Margin9.83%ATR (14)4.37Perf 10Y32.25%
Dividend Ex-DateSep 09, 2026Quick Ratio0.51Sales Y/Y TTM3.28%Profit Margin4.52%RSI (14)47.72Recom2.56
Dividend Gr. 3/5Y8.36% 7.36%Current Ratio0.87EPS Q/Q-13.43%SMA20-3.37%Beta0.22Target Price186.88
Payout187.14%Debt/Eq0.76Sales Q/Q-9.55%SMA505.17%Rel Volume0.72Prev Close179.10
Employees72,000LT Debt/Eq0.69EarningsNov 05SMA20012.31%Avg Volume2.10MPrice179.80
IPO DateFeb 21, 1973Option/ShortYes / YesEPS/Sales Surpr.4.38% 0.90%Net Debt/EBITDA4.13Volume1,517,288Change0.39%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-13-26ReiteratedRBC CapitalSector Perform$180$190
Aug-07-26ReiteratedStifel NicolausBuy$175$195
Aug-07-26ReiteratedRBC CapitalSector Perform$175$180
Aug-06-26ReiteratedJefferiesBuy$190$210
Jul-28-26InitiatedUBSBuy$190
Jul-06-26ReiteratedEvercore ISI GroupOutperform$290$180
May-11-26ReiteratedBarclaysOverweight$202$204
Apr-17-26ReiteratedPiper SandlerNeutral$170$159
Apr-14-26ReiteratedRBC CapitalSector Perform$195$175
Apr-10-26ResumedGoldman SachsNeutral$274$167
Latest News· Times ET
Sep-09-26
Sep-07-26
Sep-02-26
Aug-31-26
Aug-27-26
Aug-26-26
Aug-25-26
Aug-20-26
Aug-19-26
Aug-17-26
Aug-13-26
Company

Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
9/30/2025
FY 2024
9/30/2024
FY 2023
9/30/2023
FY 2022
9/30/2022
FY 2021
9/30/2021
FY 2020
9/30/2020
FY 2019
9/30/2019
FY 2018
9/30/2018
Total Revenue20,83921,83920,178
Cost of Goods Sold Incl. D&A11,22811,91511,053
Gross Profit9,6119,9249,125
Selling, General and Administrative Excl. Other5,2725,2774,857
Research and Development1,1471,2641,190
Other Operating Expense1,146806681
Operating Income2,0482,5782,397
Interest Expense543613528
Unusual Expense
Non-Operating Income (Expense)85-83136
Net Income Before Taxes1,5901,8822,005
Income Taxes301204300
Consolidated Net Income9411,6781,705
Net Income From Continuing Operations1,2891,6781,705
Net Income9411,6781,705
EPS (Recurring)3.325.845.88
EPS (Basic, Before Extraordinaries)3.325.845.88
EPS (Diluted)3.325.835.86
EBITDA3,8974,9574,819
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio54.1625.2432.34
Price To Sales Ratio2.371.932.72
Gross Margin46.1245.4445.22
Operating Margin9.8311.8011.88
Net Margin4.527.688.45
Shares Outstanding275287290
Market Capitalization49,44542,23254,967
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$200.47$182.12$163.77$145.42$127.07 Close Price0.00M0.31M0.62M0.93M1.24MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Feld MichaelEVP, Chief Revenue OfficerAug 26 '26Sale188.4916531,10119,720Aug 27
Polen Thomas E JrChairman, CEO and PresidentAug 13 '26Option Exercise167.2543,2787,238,246153,441Aug 14
Polen Thomas E JrChairman, CEO and PresidentAug 13 '26Sale185.004,152768,120110,163Aug 14
Goette RolandEVP and President, EMEAAug 11 '26Sale180.842,438440,88814,856Aug 12
Feld MichaelEVP, Chief Revenue OfficerJul 27 '26Sale157.137511,78520,934Jul 28
Feld MichaelEVP, Chief Revenue OfficerJun 26 '26Sale152.807511,46021,009Jun 26
Garrison Michael DavidEVP & Pres Med.Essntl&BioPharmJun 24 '26Sale145.661,100160,22613,172Jun 25
Garrison Michael DavidEVP & Pres Med.Essntl&BioPharmJun 10 '26Sale151.481,100166,62814,272Jun 11
Polen Thomas E JrChairman, CEO and PresidentJun 01 '26Option Exercise126.1620,2092,549,567125,680Jun 03
Polen Thomas E JrChairman, CEO and PresidentJun 01 '26Sale146.352,764404,511110,163Jun 03
Feld MichaelEVP, Chief Revenue OfficerMay 26 '26Sale147.357511,05121,084May 27
Feld MichaelEVP, Chief Revenue OfficerApr 27 '26Sale151.947411,24421,159Apr 28
Feld MichaelEVP, Chief Revenue OfficerMar 26 '26Sale156.837511,76221,233Mar 27
Feld MichaelEVP, Chief Revenue OfficerFeb 26 '26Sale181.847513,63821,308Feb 27
SCOTT BERTRAM LDirectorFeb 18 '26Sale182.61953174,02736,763Feb 18
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.